Co-Diagnostics, Inc. (CODX)
Stock Price:
$14.23 USD
0.19 (1.35%)
Updated Oct 27, 2020 3:59 PM EDT - Market closed
Key Info
| Market Cap |
399.62M |
| Revenue (ttm) |
25.74M |
| Net Income (ttm) |
8.09M |
| Shares Out |
28.08M |
| EPS (ttm) |
0.35 |
| PE Ratio |
40.66 |
| Forward PE |
4.43 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 27, 2020 |
| Last Price |
$14.23 |
| Previous Close |
$14.04 |
| Change ($) |
0.19 |
| Change (%) |
1.35% |
| Day's Open |
13.61 |
| Day's Range |
13.10 - 14.38 |
| Day's Volume |
1,804,164 |
| 52-Week Range |
0.85 - 30.99 |
More Stats
| Market Cap |
399.62M |
| Enterprise Value |
381.07M |
| Earnings Date (est) |
Nov 11, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
28.08M |
| Float |
26.34M |
| EPS (basic) |
0.22 |
| EPS (diluted) |
0.35 |
| FCF / Share |
-0.13 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
2.46% |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
6.92M |
| Short Ratio |
1.49 |
| Short % of Float |
26.27% |
| Beta |
-1.68 |
| PE Ratio |
40.66 |
| Forward PE |
4.43 |
| P/FCF Ratio |
n/a |
| PS Ratio |
15.53 |
| PB Ratio |
10.49 |
| Revenue |
25.74M |
| Operating Income |
7.98M |
| Net Income |
8.09M |
| Free Cash Flow |
-3.44M |
| Net Cash |
18.55M |
| Net Cash / Share |
0.66 |
| Gross Margin |
0.40% |
| Operating Margin |
31.02% |
| Profit Margin |
31.40% |
| FCF Margin |
-13.37% |
| ROA |
23.91% |
| ROE |
42.38% |
| ROIC |
172.50% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (3)
| Buy |
3 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$35.33*
(148.28% upside)
Low
30.0
Current: $14.23
High
43.0
Target: 35.33
*Average 12-month price target from 3 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|
| Revenue | 0.21 | 0.04 | 0.01 | - | 0.01 |
| Revenue Growth | 438.63% | 420.9% | - | - | - |
| Gross Profit | 0.10 | 0.03 | 0.01 | - | 0.01 |
| Operating Income | -5.89 | -6.12 | -4.56 | -1.69 | -1.97 |
| Net Income | -6.20 | -6.27 | -6.96 | -1.93 | -2.04 |
| Shares Outstanding | 16.76 | 12.48 | 10.96 | 9.88 | 9.36 |
| Earnings Per Share | -0.36 | -0.50 | -0.63 | -0.20 | -0.22 |
| Operating Cash Flow | -5.53 | -4.08 | -3.21 | -1.31 | -1.53 |
| Capital Expenditures | -0.11 | -0.04 | -0.13 | -0.01 | -0.12 |
| Free Cash Flow | -5.64 | -4.12 | -3.34 | -1.32 | -1.65 |
| Cash & Equivalents | 0.89 | 0.95 | 3.53 | 1.00 | 0.03 |
| Total Debt | - | 1.91 | - | 3.39 | 1.01 |
| Net Cash / Debt | 0.89 | -0.96 | 3.53 | -2.40 | -0.98 |
| Assets | 2.22 | 1.55 | 4.66 | 1.30 | 0.37 |
| Liabilities | 0.48 | 2.61 | 0.81 | 4.29 | 1.52 |
| Book Value | 1.74 | -1.06 | 3.85 | -2.99 | -1.15 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Co-Diagnostics, Inc. |
| Country |
United States |
| Employees |
39 |
| CEO |
Dwight Howard Egan |
Stock Information
| Ticker Symbol |
CODX |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Diagnostics & Research |
| Unique Identifier |
NASDAQ: CODX |
| IPO Date |
July 12, 2017 |
Description
Co-Diagnostics, a molecular diagnostics company, intends to manufacture and sell reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules. It also intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company was founded in 2013 and is headquartered in Salt Lake City, Utah.